{"schema_version":"secwatch.filing_event.v1","accession":"0001829126-26-008654","form_type":"8-K","ticker":"NTHI","cik":"0001979414","company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","filed_at":"2026-08-12T12:30:57+00:00","discovered_at":"2026-08-12T12:35:00.314449+00:00","generated_at":"2026-08-12T12:35:06.336816+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"NeOnc NEO100 Phase 2a meets primary endpoint: PFS-6 48.9% vs 20% benchmark","bullets":["PFS-6 48.9% (95% CI 26.3-68.1) vs 20% SOC benchmark, p=0.0047; median PFS 3.91 mo.","Median OS 26.09 months; OS rates 86.7% at 6 mo, 60.9% at 12 mo, 54.1% at 24 mo.","5 of 24 patients remain on treatment; one progression-free ~19 mo, one partial response 114 days; ORR 8.3%.","No major toxicities; adverse events predominantly low-grade; self-administered intranasally at home.","Company to request Type B FDA meeting to align on registrational path; full data at future medical meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-26-008654","json":"https://secwatch.observer/filing/0001829126-26-008654.json","markdown":"https://secwatch.observer/filing/0001829126-26-008654.md","text":"https://secwatch.observer/filing/0001829126-26-008654.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1979414/000182912626008654/0001829126-26-008654-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1979414/000182912626008654/neonctechnologies_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-12T12:35:06.336816+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}